Aprocitentan

CAS No. 1103522-45-7

Aprocitentan ( ACT-132577 )

Catalog No. M21083 CAS No. 1103522-45-7

Aprocitentan is ETA and ETB antagonist .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 222 Get Quote
10MG 335 Get Quote
25MG 566 Get Quote
50MG 806 Get Quote
100MG 1098 Get Quote
500MG 2205 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Aprocitentan
  • Note
    Research use only not for human use.
  • Brief Description
    Aprocitentan is ETA and ETB antagonist .
  • Description
    Aprocitentan is ETA and ETB antagonist .
  • Synonyms
    ACT-132577
  • Pathway
    Proteasome/Ubiquitin
  • Target
    Endogenous Metabolite
  • Recptor
    ET-A ;ET-B
  • Research Area
    Cardiovascular Disease
  • Indication
    Resistant Hypertension

Chemical Information

  • CAS Number
    1103522-45-7
  • Formula Weight
    546.19
  • Molecular Formula
    C16H14Br2N6O4S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:46 mg/mL (84.22 mM)
  • SMILES
    NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1
  • Chemical Name
    N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]sulfuric diamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Trensz F Bortolamiol C Kramberg M et al. Journal of Pharmacology & Experimental Therapeutics 2019.
molnova catalog
related products
  • Phosphocholine chlor...

    Phosphorylcholine is a small haptenic molecule is found in a wide variety of organisms. Human hepatic tumors undergo an elevation in the concentration of phosphorylcholine as the principal metabolic change is observed .

  • 5-Aminovaleric acid

    5-aminovalerate (or 5-aminopentanoic acid) is a lysine degradation product. It can be produced both endogenously or through bacterial catabolism of lysine.

  • L-(+)-Arabinose

    L-(+)-Arabinose inhibits intestinal sucrase activity, thereby reducing sucrose utilization, and consequently decreasing lipogenesis.